Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews how SALT scores are used in clinical trials for alopecia areata and provides patient images to help clinicians understand and apply these scores in practice; it reports no new clinical results.

This study found that M30 may protect against cyclophosphamide-induced alopecia in mice by enhancing hair growth and preventing abnormal hair, suggesting its potential as a treatment.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study observed that injecting mice with α-MSH resulted in black hair regrowth in shaved and plucked areas, suggesting a potential link to the agent darkening hair in animals with a specific pituitary tumor.

This study found that skin wound healing was accelerated in young but delayed in older Med1(epi-/-) mice compared to wild-type mice, suggesting age-dependent roles of MED1 in epidermal regeneration.

This study developed a spring-driven microneedle booster that improved early and cumulative delivery of minoxidil, accelerating hair regrowth compared to traditional roller methods in an androgenetic alopecia model.

This study found that the proposed Bayesian measurement-error-driven hidden Markov regression model effectively calibrated inflated covariate effect sizes in a community-based survey on androgenetic alopecia regardless of misclassification type.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This dataset provides additional exposure data and comprehensive analyses for a study on the long-term effects of particulate matter on androgenetic alopecia, but it presents no new findings.

This article shares the researchers' challenging journey in exploring the pathobiology of alopecia areata and reports no definitive clinical advances.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

This study found that a long-term astrocyte culture model can effectively study astrocyte senescence and suggests minoxidil as a potential candidate to regulate brain aging by normalizing dysregulated gene expression in aged astrocytes.

This case study reports a previously undescribed cause of drug-induced autoimmune hepatitis triggered by para-aminobenzoic acid (PABA), emphasizing the need for caution with this supplement.

Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.

This study suggests that the down-regulation of 14-3-3 proteins in wild-type keratinocytes, absent in Smad4 mutant keratinocytes, might contribute to the failure of hair follicles to initiate catagen in Smad4 knockout mice.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

In this case report, interferon-alpha treatment for a man with hemophilia and hepatitis C was associated with unexpected diffuse hair growth, likely caused by the medication.

In this study, adrenalectomy in black rats on a vitamin B-deficient diet restored hair growth and melanin deposition, effects reversed using adrenal cortical hormones.

This study found that A(3)B(5) downregulates melanin production and suppresses melanoma cell growth by promoting proteasomal degradation of TRP-2.

This article reports on three new cases of Birt–Hogg–Dubé Syndrome and emphasizes the role of genetic analysis in its diagnosis due to clinical challenges.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

This study analyzed clinical manifestations of dermatomyositis in 18 patients, reporting common symptoms such as skin rash, proximal muscle weakness, and elevated serum markers, with treatment typically involving prednisolone and hydroxychloroquine.

In this study, dutasteride treatment in retinitis pigmentosa mice increased photoreceptor survival and reduced glial activation, suggesting it may offer a neuroprotective effect.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This study found that methanol extract of Mimosa pudica showed dose-dependent sedative effects in mice, suggesting its potential for developing new sedative and anti-anxiety medications.

Baricitinib helps with early hair regrowth in people with alopecia areata.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This case report describes an autoimmune hepatitis patient who achieved remission with mycophenolate mofetil and corticosteroids after intolerance to azathioprine-based therapy.

In this study, mice lacking the Mcpip1 gene in their myeloid cells did not develop SCC-like tumors but instead showed increased melanocyte activity and hair loss, indicating a distinct role for myeloid Mcpip1 in skin cancer development compared to keratinocyte Mcpip1.